These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 1490681)

  • 1. Proinsulin as a possible therapeutic agent.
    Hadjidakis DJ; Raptis SA
    Horm Metab Res Suppl; 1992; 26():131-7. PubMed ID: 1490681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus.
    Glauber HS; Henry RR; Wallace P; Frank BH; Galloway JA; Cohen RM; Olefsky JM
    N Engl J Med; 1987 Feb; 316(8):443-9. PubMed ID: 3543679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the prolonged hypoglycemic effect of human proinsulin in diabetes mellitus.
    Laube H; Pinter W; Federlin K
    Horm Metab Res Suppl; 1988; 18():12-5. PubMed ID: 3056806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
    Heinemann L; Heise T; Klepper A; Ampudia J; Bender R; Starke AA
    Diabete Metab; 1995 Dec; 21(6):415-9. PubMed ID: 8593922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of hormonal counterregulation during GCIIS-guided hypoglycemia tests using human proinsulin and human insulin (recombinant DNA).
    Müller-Esch G; von der Lühe C; Ball P; Henkel E; Schlüter KJ; Wood WG; Scriba PC
    Horm Metab Res Suppl; 1988; 18():24-33. PubMed ID: 2847967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of glucagon secretion.
    Young A
    Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human proinsulin: bioactivity and pharmaco-kinetics after intravenous and subcutaneous administration.
    Schatz H; Ammermann S
    Horm Metab Res Suppl; 1988; 18():1-5. PubMed ID: 3056805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical investigations into the modification of the effect of endogenous and exogenous insulin by human proinsulin in type II and type I diabetics.
    Bellenberg S; Schröder KE; Schlüter KJ; Bottermann P; Zilker T; Gray P
    Horm Metab Res Suppl; 1988; 18():77-83. PubMed ID: 3056817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosynthetic human proinsulin, a new therapeutic compound for diabetics? A comparative study of biosynthetic human proinsulin with biosynthetic human insulin.
    Rosak C; Boehm BO; Althoff PH; Schöffling K
    Horm Metab Res Suppl; 1988; 18():16-21. PubMed ID: 3056807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactivity and pharmacokinetics of human proinsulin in comparison to human insulin after intravenous and subcutaneous injection.
    Schatz H; Ammermann S; Laube H; Federlin K
    Horm Metab Res; 1988 Jul; 20(7):445-9. PubMed ID: 3049293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of basal delivery of insulin by proinsulin in type I diabetic patients under CSII.
    Kerner W; Wallmüller G; Beischer W; Pfeiffer EF
    Horm Metab Res Suppl; 1988; 18():74-7. PubMed ID: 3056816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycemic effect of subcutaneously injected biosynthetic human proinsulin in healthy man.
    Pycior M; Kemmer FW; Berger M
    Horm Metab Res Suppl; 1988; 18():22-4. PubMed ID: 3056808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts in extracellular signaling for insulin action: the single gateway hypothesis.
    Bergman RN
    Recent Prog Horm Res; 1997; 52():359-85; discussion 385-7. PubMed ID: 9238859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance.
    Pfützner A; Kann PH; Pfützner AH; Kunt T; Larbig M; Weber MM; Forst T
    Clin Lab; 2004; 50(9-10):567-73. PubMed ID: 15481632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is daytime insulin more physiologic and less atherogenic than bedtime insulin?
    Kanat M
    Med Hypotheses; 2007; 68(6):1228-32. PubMed ID: 17145138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action profile of biosynthetic human proinsulin trials with the BIOSTATOR in metabolically normal subjects.
    Bottermann P; Wahl K; Ermler R; Gray IP; Hales CN
    Horm Metab Res Suppl; 1988; 18():6-11. PubMed ID: 3056813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites.
    Tillil H; Frank BH; Pekar AH; Broelsch C; Rubenstein AH; Polonsky KS
    Endocrinology; 1990 Nov; 127(5):2418-22. PubMed ID: 2226325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic effects of biosynthetic human proinsulin in type 2 diabetes mellitus.
    Klauser R; Prager R; Watschinger B; Schernthaner G
    Eur J Clin Invest; 1989 Oct; 19(5):466-71. PubMed ID: 2511023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.